Astellas Pharma Inc: Urinary Bladder, Overactive trials

The registry lists 70 Urinary Bladder, Overactive studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 25 have results posted.

Phase 1 6Phase 2 4Phase 3 24Phase 4 16No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)TerminatedNCT04641975Phase 3Results posted
• A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive BladderCompletedNCT04562090Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)CompletedNCT02757768Phase 4Results posted
• Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT02751931Phase 3Results posted
• A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)CompletedNCT02656173Phase 4Results posted
• Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.CompletedNCT02294396Phase 4Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)CompletedNCT02216214Phase 4Results posted
• A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)CompletedNCT02138747Phase 4Results posted
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderCompletedNCT02045862Phase 3Results posted
• A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)CompletedNCT01981954Phase 3Results posted
• This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive BladderCompletedNCT01972841Phase 3Results posted
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)CompletedNCT01908829Phase 3Results posted
• A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder PatientsCompletedNCT01745094Phase 4Results posted
• A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076CompletedNCT01655069Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.CompletedNCT01638000Phase 3Results posted
• A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active DrugCompletedNCT01565707Phase 3Results posted
• A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT01565694Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderCompletedNCT01340027Phase 2Results posted
• Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.CompletedNCT01093534Phase 4Results posted
• A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00912964Phase 3Results posted
• Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00689104Phase 3Results posted
• Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00688688Phase 3Results posted
• A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00662909Phase 3Results posted
• Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of LifeCompletedNCT00573508Phase 4Results posted
• Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)CompletedNCT00431041Phase 4Results posted
• A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic BurdenCompletedNCT03903094
• Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia OceaniaCompletedNCT03602508
• A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and ChinaCompletedNCT03572231
• Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder SymptomsCompletedNCT02715024Phase 4
• Reproducibility Study of OABSS and Its Response to TreatmentCompletedNCT02667470Phase 4
• Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular DiseaseCompletedNCT02570035
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)CompletedNCT02526979Phase 1
• A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)CompletedNCT02386072
• A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical PracticeCompletedNCT02320773
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive BladderCompletedNCT02211846Phase 1
• A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other AntimuscarinicsCompletedNCT02087098
• Drug Use-Results Survey of Betanis Tablets in JapanCompletedNCT01919047
• Long-Term Specified Drug Use-results Survey of Betanis TabletsCompletedNCT01901120
• Specified Drug Use-results Survey of Betanis TabletsCompletedNCT01898624
• Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)CompletedNCT01799902
• Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)CompletedNCT01747577Phase 4
• Vesitirim™ in Men Postmarketing Observational StudyCompletedNCT01639794
• Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01604928Phase 2
• An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional UrodynamicsTerminatedNCT01540786Phase 1
• Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive BladderCompletedNCT01539707Phase 1
• Post Marketing Survey of Vesicare in JapanCompletedNCT01489709
• A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin TreatmentCompletedNCT01318837Phase 4
• A Study Measuring and Tracking Changes in Overactive Bladder (OAB) MedicationWithdrawnNCT01317810
• Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and AdolescentsCompletedNCT01262391Phase 1
• A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to TreatmentCompletedNCT01122563
• Reproducibility Study of Overactive Bladder Symptom Score [OABSS]CompletedNCT01122550
• A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)TerminatedNCT01099345
• A Study of YM178 in Subjects With Symptoms of Overactive BladderCompletedNCT01043666Phase 3
• Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal SubjectsCompletedNCT01029015
• Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder PatientsCompletedNCT00985387
• A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive BladderCompletedNCT00966004Phase 3
• Reproducibility Study of Over Active Bladder Symptom Score [OABSS]CompletedNCT00901251
• A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy SubjectsCompletedNCT00856570Phase 1
• A Long-term Study of YM178 in Symptomatic Overactive Bladder PatientsCompletedNCT00840645Phase 3
• Solifenacin Succinate Versus Tolterodine 4mg Once DailyCompletedNCT00802373Phase 3
• Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency SymptomsCompletedNCT00801944Phase 3
• Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic HyperplasiaCompletedNCT00771394Phase 4
• A Study of YM178 in Patients With Symptomatic Overactive BladderCompletedNCT00527033Phase 2
• Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder SymptomsCompletedNCT00463541Phase 3
• A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)CompletedNCT00454896Phase 3
• Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive BladderCompletedNCT00454740Phase 3
• A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder PatientsCompletedNCT00368706Phase 3
• A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)CompletedNCT00337558Phase 4
• A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)CompletedNCT00337090Phase 2
• A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive BladderCompletedNCT00189800Phase 3